Healthwise

Tardive Dyskinesia


National Organization for Rare Disorders, Inc.

Synonyms

  • Linguofacial Dyskinesia
  • Oral-facial Dyskinesia
  • Tardive Dystonia
  • Tardive Oral Dyskinesia
  • TD

Disorder Subdivisions

  • None

Related Disorders List

Information on the following diseases can be found in the Related Disorders section of this report:

  • Tourette Syndrome
  • Huntington Disease
  • Cerebral Palsy
  • Dystonia

General Discussion

Tardive Dyskinesia (TD) is an involuntary neurological movement disorder caused by the use of neuroleptic drugs that are prescribed to treat certain psychiatric or gastrointestinal conditions. Long-term use of these drugs may produce biochemical abnormalities in the area of the brain known as the striatum. The reasons that some people who take these drugs may get Tardive Dyskinesia, and some people do not, is unknown. Tardive Dystonia is believed to be the more severe form of Tardive Dyskinesia.

Symptoms

Tardive Dyskinesia is characterized by involuntary and abnormal movements of the jaw, lips and tongue. Typical symptoms include facial grimacing, sticking out the tongue, sucking or fish-like movements of the mouth. In some cases, the arms and/or legs may also be affected by involuntary rapid, jerking movements (chorea), or slow, writhing movements (athetosis). Symptoms of Tardive dystonia include the facial movements of Tardive dyskinesia plus muscle spasms in other parts of the body.

Causes

Tardive Dyskinesia is caused by long-term use of a class of drugs known as neuroleptics. Neuroleptic drugs are often prescribed for management of certain mental, neurological, or gastrointestinal disorders. Neuroleptic drugs block dopamine receptors in the brain. Dopamine is a neurotransmitter which is a chemical that helps brain cells to communicate. Although most cases occur after a person has taken these drugs for several years, some cases may occur with shorter use of neuroleptic drugs.

Affected Populations

Tardive Dyskinesia affects individuals who have been taking neuroleptic drugs for a long period of time. A high percentage of schizophrenic people who have spent long periods of time taking these drugs have a high risk of developing TD. However, neuroleptic drugs are also prescribed for some digestive disorders and other neurologic illnesses.

Related Disorders

Symptoms of the following disorders can be similar to those of Tardive Dyskinesia. Comparisons may be useful for a differential diagnosis:

Huntington’s Disease (also known as Huntington's Chorea or "Woody Guthrie’s disease") is an inherited neurological illness. Those affected experience involuntary movements, loss of motor control, changes in gait, loss of memory, and in some cases, dementia. In general, the first symptoms of HD appear between thirty and fifty years of age. HD runs a progressive course, severely weakening patients usually over a ten to twenty year period, whereas there is no degeneration in Tardive Dyskinesia. (For more information on this disorder, choose "Huntington" as your search term in the Rare Disease Database.)

Cerebral Palsy is a disorder characterized by impaired muscle control or coordination (motor output system) resulting from injury to the brain during its early stages of development (the fetal, perinatal, or early childhood stages). There may be associated problems with sensory input, such as vision or hearing defects, central processing (such as communication), intellectual or perceptual deficits, and/or seizures. People with CP can have slow facial and tongue movements, which may resemble TD. (For more information on this disorder, choose "Cerebral Palsy" as your search term in the Rare Disease Database.)

Tourette Syndrome is a neurological movement disorder which begins in childhood between the ages of two and sixteen. The disorder is characterized by involuntary muscular movements called "tics", and uncontrollable vocal sounds. Sometimes inappropriate words may unavoidably be spoken. Tourette Syndrome is not a degenerative disorder and those affected can expect to live a normal life span. Neuroleptic drugs such as haloperidol and pimozide can be prescribed as treatments for TS, so it may be difficult to determine whether facial and tongue movements in TS patients are caused by the disorder or the drugs. (For more information on this disorder, choose "Tourette" as your search term in the Rare Disease Database.)

Dystonia is a group of complex movement disorders with various in its causes, treatments, progression, and symptoms. These neurological conditions are characterized by involuntary muscle contractions which force certain parts of the body into abnormal, sometimes painful movements and positions. Dystonia is not a single disease, but a set of symptoms that often cannot be attributed to a single cause. Both genetic and non-genetic factors contribute to all forms of dystonia. The major characteristics of all forms of dystonia are twisting, repetitive writhing movements affecting particular parts of the body (for example, the neck or an arm). Tardive dystonia is believed to be the most severe form of Tardive dyskinesia. (For more information on this disorder, choose "Dystonia" as your search term in the Rare Disease Database.)

Standard Therapies

Treatment of Tardive Dyskinesia initially consists of discontinuing the neuroleptic drug as soon as involuntary facial movements are noticed in people taking neuroleptic drugs. In some cases, physicians may decide to reinstitute the neuroleptic drug if the Tardive Dyskinesia symptoms do not disappear and if they become very severe after medication is discontinued.

Investigational Therapies

Studies are ongoing to determine possible new drug therapies for the treatment of Tardive Dyskinesia. These drugs include choline, lithium, bromocriptine, baclofen, methyldopa, valproate, clonidine, propranolol, amantadine, clonazepam, and nifedipine. Many other experimental drugs are being tested to reduce or eliminate the symptoms of Tardive Dyskinesia. For more information about these studies, please contact the agencies listed in the Resources section of this report.

References

ONLINE MENDELIAN INHERITANCE IN MAN (OMIM). Victor A. McKusick, Editor; Johns Hopkins University, Last Edit Date 1/31/95, Entry Number 272620.

INTERNAL MEDICINE, 2nd Ed.: Jay H. Stein, ed.-in-chief; Little, Brown and Co., 1987. Pp. 2160.

DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS: DSM IV, 4th Ed.: A. Frances et. al., Editors; American Psychiatric Association, 1994. Pp. 679-80 & 747-49.

TREATMENTS OF PSYCHIATRIC DISORDERS, 2nd Ed.: Glen O. Gabbard, M.D., Editor; American Psychiatric Association, 1995. Pp. 985-86.

SUPPRESSION OF TARDIVE DYSKINESIA WITH AMOXAPINE: CASE REPORT. D. A. DMello et al.; J Clin Psychiatry (Mar 1986; 47(3)). P. 148.

FACIAL DYSKINESIA. J. Jankovic et al.; Adv Neurol (1988). P. 49.

CONVENTIONAL VS NEWER ANTIPSYCHOTICS IN ELDERLY PATIENTS. D. V. Jeste et al.; Am j Geriatr Psychiatry (Winter 1997; 7(1)). Pp. 70-76.

INCIDENCE OF TARDIVE DYSKINESIA IN EARLY STAGES OF LOW-DOSE TREATMENT WITH TYPICAL NEUROLEPTICS IN OLDER PATIENTS. D. V. Jeste et al.; Am J Psychiatry (Feb 1999; 156(2)). Pp. 309-11.

RANDOMISED DOUBLE-BLIND COMPARISON OF THE INCIDENCE OF TARDIVE DYSKINESIA IN PATIENTS WITH SCHIZOPHRENIA DURING LONG-TERM TREATMENT WITH OLANZAPINE OR HALOPERIDOL. C. M. Beasley et al.; Br J Psychiatry (Jan 1999; 174). Pp. 23-30.

MANAGING ANTIPSYCHOTIC-INDUCED TARDIVE DYSKINESIA. G. Gardos; Drug Saf (Feb 1999; 20(2)). Pp. 187-93.

TARDIVE DYSKINESIA IN AFFECTIVE DISORDERS. J. M. Kane; J Clin Psychiatry (1990; 60(5)). Pp. 43-47.

Resources

WE MOVE (Worldwide Education and Awareness for Movement Disorders)
204 West 84th Street
New York, NY 10024
USA
Tel: 2128758312
Fax: 2128758389
Email: wemove@wemove.org
Internet: http://www.wemove.org

National Mental Health Association
2001 North Beauregard Street
12th Floor
Alexandria, VA 22311
USA
Tel: 7036847722
Fax: 7036845968
Tel: 8009696642
TDD: 8004335959
Email: infoctr@nmha.org
Internet: http://www.nmha.org

National Alliance for the Mentally Ill
Colonial Place Three
2107 Wilson Blvd.
Suite 300
Arlington, VA 22201-3042
ISA
Tel: 7035247600
Fax: 7035249094
Tel: 8009996264
TDD: 7035167227
Email: membership@nami.org
Internet: http://www.nami.org

NIH/National Institute of Mental Health
6001 Executive Blvd
Rm 8184, MSC 9663
Rockville, MD 20892-9663
Tel: (301)443-4513
Email: nimhinfo@nih.gov
Internet: http://www.nimh.nih.gov/

National Institute of Neurological Disorders and Stroke (NINDS)
31 Center Drive
8A07
Bethesda, MD 20892-2540
Tel: (301)496-5751
Fax: (301)402-2186
Tel: (800)352-9424
Email: braininfo@ninds.nih.gov
Internet: http://www.ninds.nih.gov/

The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only. NORD recommends that affected individuals seek the advice or counsel of their own personal physicians.

It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report

This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.

For additional information and assistance about rare disorders, please contact the National Organization for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site www.rarediseases.org or email orphan@rarediseases.org

Last Updated:  8/7/2007
Copyright  1987, 1989, 1995, 1998, 1999, 2007 National Organization for Rare Disorders, Inc.



This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.